ATH-063 is a novel, oral, first-in-class, small molecule therapeutic targeting both inflammation and direct mucosal healing in patients with ulcerative colitis and Crohn's disease LOS ANGELES, CA / ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback